Chun Eung Park

Title: Innovations of Chun Eung Park

Introduction

Chun Eung Park is a notable inventor based in Daejeon, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that modulate glutamate receptors. With a total of 4 patents to his name, Park's work is recognized for its potential impact on treating disorders related to glutamate dysfunction.

Latest Patents

One of his latest patents involves imidazopyrimidine and imidazotriazine derivatives, along with a pharmaceutical composition comprising these compounds. The patent details a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof. This compound acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5). It is particularly useful in the prevention or treatment of disorders mediated by glutamate dysfunction and mGluR5.

Career Highlights

Chun Eung Park is currently associated with Sk Biopharmaceuticals Co., Ltd. His work at this company has allowed him to focus on innovative pharmaceutical solutions that address critical health issues. His research and inventions are paving the way for new therapeutic approaches in medicine.

Collaborations

Park has collaborated with several professionals in his field, including Young Koo Jang and Yong Je Shin. These collaborations have enhanced the scope and impact of his research, contributing to advancements in pharmaceutical sciences.

Conclusion

Chun Eung Park's contributions to the field of pharmaceuticals through his innovative patents highlight his role as a significant inventor. His work continues to influence the development of treatments for disorders related to glutamate dysfunction.